Skip to main content

Yale scientists edit genetic diseases out of mice before birth; humans are next

Gene-editing techniques such as CRISPR/Cas9 can be used to astonishing, potential life-altering effect, such as one demonstration involving a possible treatment for ALS. Researchers at Carnegie Mellon University and Yale University have now made a significant breakthrough in the technology’s usefulness — by demonstrating how gene editing can be used to treat genetic conditions during fetal development.

While so far it has only been showcased in an experiment with mice, in the future it could help treat the millions of children who are born each year with severe genetic disorders or birth defects. At present, some of these genetic conditions can be detected during pregnancy, although they cannot be corrected during fetal development.

Recommended Videos

“This is the first description of a genetic disease corrected by gene editing delivered to a developing mammalian fetus,” David Stitelman, assistant professor of surgery at Yale School of Medicine, told Digital Trends. “The gene editing reagents are in the form of peptide nucleic acids called PNA, which bind chromosomal DNA in a specific manner. The PNAs are designed to bind just upstream or downstream to a disease-causing mutation. The cell’s own editing machinery detects where the PNA has bound the chromosome and removes that segment.”

In their study, the researchers used the technique to correct 6 percent of the mutations in the gene causing beta thalassemia, a blood disorder that reduces the production of hemoglobin. Just one injection of the PNA complex into the amniotic fluid of pregnant mice caused dramatic improvements in their affected offspring. These improvements were significant enough that the mice were functionally cured of the disease.

“This work can be translated in human patients clinically,” Stitelman continued. “This approach could be used for most diseases where a known genetic mutation causes the disease. Many of these diseases are devastating and currently without cure. Our approach corrects the disease at the most fundamental level and in the most rational way. At this point, there are about 6,000 diseases that fit that description that impact about one in 200 babies.”

Possible diseases the work could help treat include neurologic diseases like Tay Sachs disease or spinal muscular atrophy, blood diseases such as sickle cell anemia, thalassemia and hemophilia, muscle diseases like muscular dystrophy, and diseases of the airway and intestinal tract including cystic fibrosis.

“We are [now] using this technology in other mouse models of human genetic disease,” Stitelman said. “We are continually optimizing the PNA/DNA editing reagents and the nanoparticles that encapsulate those agents. For future translation, we need to determine safety and efficacy in larger animals before applying this technology clinically.”

A paper describing the work was recently published in Nature Communications.

Luke Dormehl
Former Digital Trends Contributor
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Trump administration prepares to end Biden’s EV tax incentive, report says
president biden drives 2022 ford f 150 lightning electric pickup truck prototype visits rouge vehicle center

If you’re looking to buy or lease an electric vehicle (EV) and benefit from the Biden administration’s $7,500 tax incentive, you’d better act soon.

The transition team of the incoming Trump administration is already planning to end the credit, according to a report from Reuters citing sources with direct knowledge of the matter.

Read more
Hertz is selling used Teslas for under $20K, Chevrolet Bolt EVs under $14K
2018 Chevrolet Bolt EV

Tesla CEO Elon Musk recently nixed hopes of a regular Tesla model ever selling for $25,000.

But he was talking about new models. For car rental company Hertz, the race to sell used Teslas and other EVs at ever-lower prices is not only still on but accelerating.

Read more
Never mind slowing sales, 57% of drivers will likely have an EV in 10 years

Sales of electric vehicles (EVs) have slowed globally over the past few years. But should EV makers cater more to the mainstream, it’s likely that 57% of drivers will have an EV in 10 years, consulting firm Accenture says.

Last year, nearly 14 million EVs were sold globally, representing a 35% year-on-year increase. But it was much slower than the 55% sales growth recorded in 2022 and the 121% growth in 2021.

Read more